Caspofungin

Drugs

Volumn 61, Issue 8, 2001, Pages 1121-1129

  Keating, G M ^a   Jarvis, B ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; GLUCAN;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; DRUG TOLERABILITY; FEVER; HUMAN; IMMUNE DEFICIENCY; INJECTION PAIN; MOUSE; MYCOSIS; NAUSEA; NONHUMAN; REVIEW; VOMITING;

ASPERGILLUS; CANDIDA; FUNGI;

EID: 0034911568     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161080-00007     Document Type: Review

References (42)

1. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer
2. Current management of fungal infections in immunocompromised patients and polyene lipid complexes for treatment of invasive fungal infection
3. Fungal cell wall inhibitors: Emphasis on clinical aspects
4. Comparative in vitro susceptibility of clinical trial isolates to the glucan synthesis inhibitor antifungal caspofungin (Cancidas™, MK-0991)
5. In vitro susceptibility of clinical trial isolates of Aspergillus spp. to the glucan synthesis inhibitor caspofungin acetate (Cancidas™, MK-0991)
6. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
7. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates
8. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi
9. In vitro synergy studies with caspofungin and amphotericin B against Aspergillus and Fusarium
10. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species
11. In vitro activity of Cancidas (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance
12. In vitro evaluation of pneumocandin activity against clinical isolates of yeasts
13. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
14. In vitro studies with L-743,872, a water soluble pneumocandin: A comparative study
15. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species
16. In-vitro antifungal activity of L-743,872, a new penumocandin, against sensitive and resistant Torulopsis and Candida species
17. Comparative in vitro susceptibility of clinical trial isolates to the echinocandin antifungal MK-991
18. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents
19. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans
20. In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: Influence of assay conditions
21. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds
22. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
23. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice
24. Low doses of the pneumocandin, L-743,872, are effective for prevention and treatment in an animal model of pulmonary aspergillosis
25. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872
26. Treatment of murine disseminated candidiasis with L-743,872
27. Activity of pneumocandin L-743872 in a CD4+ T-cell deficient mouse model of oropharyngeal and gastrointestinal candidiasis
28. Evaluation of pneumocandin L-743872 in neutropenic mouse models of disseminated candidiasis and aspergillosis
29. Preclinical efficacy of MK-0991 in pancytopenic mouse models of disseminated candidiasis and aspergillosis
30. Treatment of histoplasmosis with MK-991 (L-743,872)
31. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model
32. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii
33. Single- and multiple-dose pharmacokinetics of the antifungal agent MK-0991 in man
34. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872)
35. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine
36. Single dose caspofungin pharmacokinetics in healthy elderly subjects
37. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory or intolerant (I) to amphotericin B (AMB), AMB lipid formulations (lipid AMB), or azoles
38. A randomized, double-blind, multicenter trial of MK-991 vs. amphotericin B in the treatment of Candida esophagitis in adults
39. A randomized, double-blind, multicenter trial of MK-0991, an echinocandin antifungal agent, vs amphotericin B for the treatment of oropharyngeal and esophageal candidiasis in adults
40. Safety of caspofungin acetate (CA) in the treatment of fungal infections
41. A phase I study of caspofungin evaluating the potential for drug interactions with itraconazole, the effect of gender and the use of a loading dose regimen